SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

04 Mar 2024 06:30:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

29 Feb 2024 08:30:13 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

27 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 Jan 2024 07:00:50 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

08 Jan 2024 06:30:44 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023 07:00:25 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

08 Dec 2023 16:05:10 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

05 Dec 2023 00:32:11 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

04 Dec 2023 16:13:24 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

27 Nov 2023 18:04:15 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

16 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

02 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting

01 Nov 2023 06:30:06 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

11 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

02 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

05 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

30 May 2023 06:30:10 By Nasdaq GlobeNewswire